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Abstract
Gefitnib is an oral agent of epidermal growth factor receptor tyro-
sine kinase inhibitor, and it has a certain efficacy against non-small 
cell lung cancer. There are some reports that the non-small cell lung 
cancer patients who experienced disease progression after respond-
ing to gefitinib were again sensitive to re-administration of gefitinib 
following temporary cessation of gefitinib. This is the case report 
showing a remarkable effect of gefitinib re-treatment in a patient 
with metastatic invasive adenocarinoma who had experienced fa-
vorable results from the initial treatment with gefitinib.
Keywords: Gefitinib; Retreatment; Lepidic predominant adenocar-
cinoma
Introduction
The  over-activation  of  epidermal  growth  factor  receptor 
(EGFR) is involved in proliferation and survival of cancer 
cells. Gefitinib is an oral agent of epidermal growth factor 
receptor tyrosine kinase inhibitor, and it has a certain ra-
diographic and symptomatic efficacy against non-small cell 
lung cancer. It was approved in Japan in July 2002 for the 
treatment of patients with non-small cell lung cancer [1], es-
pecially in females, those with an adenocarcinoma histology, 
those who have never smoked, and patients with a good per-
formance status [1, 2 ]. There are some reports of non-small 
cell lung cancer patients who experienced disease progres-
sion after initially responding to gefitinib, who were again 
sensitive  to  re-administration  of  gefitinib  following  tem-
porary cessation of gefitinib [3-6]. It is of interest whether 
re-challenging with gefitinib after treatment of a recurrence 
site contributes to the patient’s survival by achieving partial 
response or by maintaining the disease stable for a long time. 
In the present study, we report on a case of a remarkable 
effect of gefitinib re-treatment in a lung cancer patient with 
lepidic predominant adenocarcinoma who had experienced 
favorable results from initial treatment with gefitinib.
Case Report
A 72-years-old nonsmoker woman with fever, chronic cough, 
purulent sputum, and dyspnea, who had previously taken 
medication for bronchial asthma for 16 years, was admitted 
because chest X-ray showed a 5 cm-sized mass-like consoli-
dation in the right lower lung field. Chest computed tomog-
raphy also noted pneumonic infiltrations in the middle lobe 
and right lower lobe of the right lung. We started intravenous 
antibiotics upon diagnosis as possible pneumonia. Bronchial 
washing was performed because we could not exclude malig-
nancy, such as invasive adenocarcinoma. Washing cytology 
was negative for malignancy. Although symptoms were im-
proved with antibiotics, a follow-up chest X-ray was not im-
proved. Furthermore, chest CT scans after 4 months showed 
aggravated infiltrations and newly developed nodules in both 
of the upper lung fields (Fig. 1A). Percutaneous transthoracic 
needle aspiration was performed on the patient. Finally, lep-
idic predominant adenocarcinoma was diagnosed (Fig. 2). 
After this diagnosis, the patient received the three courses 
of first-line chemotherapy with docetaxel plus carboplatin as 
stage IV (T4N0M1) with lung-to-lung metastasis. However, 
the treatment response was progressive disease (Fig. 1B). 
Thus, the patient began to take gefitinib at 250 mg/day be-
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cause EGFR gene analysis in this patient showed a deletion 
mutation in exon 19 and point mutation L858R in exon 21 by 
direct sequence method (Fig. 3). A remarkable tumor regres-
sion was found as nearly complete response was achieved 
after 2 months (Fig 1C). The tumor size of right middle lobe 
and lower lobe was decreasing, and the metastatic nodules 
of both upper lobes had nearly disappeared. This response 
lasted for almost 15 months (Fig 1D). Although gefitinib 
Figure 1. A: Initial chest CT scan, a consolidative mass in RML and RLL with multiple hematogenous metastatic nodules in 
BUL. B: Chest CT scan before treatment with 250 mg gefitinib, more increased consolidative mass in the right lung field. C: 
Chest CT scan 6 months after treatment with 250 mg gefitinib, much improved consolidative mass in the right lung and mark-
edly improved hematogenous metastasis in BUL. D: Chest CT scan 13 month after treatment with 250 mg gefitinib, no interval 
change compared with the previous CT scan.
Figure 3. EGFR gene analysis.
Figure 2. Photomicroscopic finding of lepidic predominant 
adenocarcinoma (H&E, × 400).
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was discontinued because the disease had progressed, the 
patient with a good performance status received 2 courses 
of pemetrexed and 4 sequential courses of gemcitabine/
vinorelbine chemotherapy (Fig 4A, B). Despite continued 
chemotherapy,  the  patient  showed  radiographic  progres-
sion.  Thus,  we  commenced  re-treatment  with  gefitinib. 
Two months later, a partial response had been achieved at 
the primary tumor and metastatic lesions (Fig 4C). The re-
sponse continued even after 4 months. Even after that, the 
repeated re-administration of gefitinib after 3 to 4 months 
had elapsed was shown stable disease. The patient was still 
alive 5 years after she was initially diagnosed with meta-
static invasive adenocarcinoma.
Discussion
  
We found that a lung cancer patient with lepidic predominant 
adenocarinoma who had disease progression after a remark-
able initial response to gefitinib was again sensitive to re-ad-
ministration of gefitinib after a certain time had elapsed since 
the previous gefitinib treatment. So far, there are several pa-
tients with adenocarcinoma who, after having experienced 
disease progression after completely responding to gefitinib, 
have responded to re-treatment with gefitinib following tem-
porary cessation of gefitinib [3-6]. To our knowledge, it is 
believed that this is the case report showing a remarkable 
effect of gefitinib re-treatment in a patient with metastatic 
invasive adenocarinoma who had experienced favorable re-
sults from the initial treatment with gefitinib.
Although  an  international  core  panel  of  experts  in 
IASLC/ATS/ERS recently argued that “lepidic predominant 
adenocarcinoma (LPA)” or “invasive mucinous adenocarci-
noma” should be used instead of the term bronchioloalveolar 
carcinoma (BAC) [7], the term of BAC could be reserved for 
those tumors meeting the 1999/2004 criteria set forth by the 
World Health Organization, which is a form of adenocarci-
noma with unique clinical, radiological and epidemiological 
features [8]. As in our case, LPA with diffuse parenchymal 
disease is often mistaken for pneumonia or pneumonitis. Al-
though patients may be cured after surgical resection of focal 
LPA, there is no optimal established therapy for multilobar or 
Figure 4. A: Chest CT scan after treatment with 2 courses of pemetrexed, more aggravated consolidative mass in RLL and 
more enlarged metastatic nodules in RML and RLL. B: Chest CT scan after treatment with 4 courses of gemcitabine/vinorel-
bine, more aggravated consolidative mass in RLL and more enlarged metastatic nodules in both lungs. C: Chest CT scan 2 
months after re-treatment with 250 mg gefitinib, slightly decreased consolidative mass in RLL and markedly decreased meta-
static nodules in both lungs.
218                                                                                                                                                                                                                                                                                                                                                                                                                                             219J Clin Med Res  •  2012;4(3):216-220 Lee et al
Articles © The authors   |   Journal compilation © J Clin Med Res and Elmer Press™   |   www.jocmr.org
recurrent disease. Some clinical trials have been performed 
specifically with patients with LPA, based on the notion that 
these tumors may be less sensitive to standard chemotherapy 
and that the biology of LPA differs from that of other adeno-
carcinomas [9]. Recently, it has been reported that mutations 
in the tyrosine kinase domain of the EGFR are associated 
with the sensitivity of non-small cell lung cancer to gefitinib 
[10]. Treatment with EGFR tyrosine kinase inhibitors (TKI) 
gefitinib has led to prompt and dramatic radiologic and clini-
cal improvement in selected patients with metastatic non-
small cell lung cancer. Deletions or amino acid substitutions 
in exons 18, 19, and 21 were found in tumors sensitive to 
gefitinib. These mutations were frequently found in females, 
those with adenocarcinoma histology, those of Asian ethnic-
ity, and those with adenocarcinomas of the bronchioloalveo-
lar subtype who had never smoked. In addition, Cadranel et 
al [11] demonstrated that gefitinib is suitable as a first-line 
treatment for advanced adenocarcinoma, particularly in pa-
tients with lepidic predominant subtype. Our case showed 
deletion mutation in exon 19 and point mutation L858R in 
exon 21 as well as pathologically lepidic predominant ad-
enocarcinoma. Based on current studies, we could explain 
why EGFR-TKI in this patient had a prompt and dramatic 
radiologic and clinical improvement.
Unfortunately, even in gefitinib responders, disease pro-
gression occurs and is inevitable. Some reports present that 
despite initial responses, patients eventually progress by un-
known mechanisms of “acquired” resistance, a secondary mu-
tation in exon 20, which leads to substitution of methionine 
for threonine at position 790 (T790M) in the kinase domain 
[12].
More than 4 months after the discontinuation of the ini-
tial gefitinib treatment, the patient was retreated with gefi-
tinib due to further progression of the disease. The partial 
response lasted for 4 months. Re-treatment with gefitinib 
is known to be effective. So far, little is known about the 
mechanism of resensitization to gefitinib. Kurata et al [6] 
suggested three possible explanations for the resensitization 
in some patients with adenocarcinomas who develop recur-
rence after successful treatment with gefitinib. First, resis-
tance to gefitinib may naturally change over time. Secondly, 
the proportion of sensitive or resistant cells might have been 
modified by chemotherapy after the first treatment with ge-
fitinib. Thirdly, treatment with cytotoxic chemotherapy pro-
duces genetic changes in EGFR or other unknown associ-
ated genes that regulate resistance to gefitinib.  
In  conclusion,  we  investigated  a  lung  cancer  patient 
with  lepidic  predominat  adenocarcinoma  who  had  been 
successfully controlled with an initial treatment with gefi-
tinib for more than 15 months, who then relapsed and was 
retreated with gefitinib. The partial response of the patient 
continued for more than 4 months with re-treatment with ge-
fitinib monotherapy. Further examinations are warranted to 
clarify the mechanisms of adenocarcinoma sensitivity and 
resistance to gefitinib.
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